I write Exits & Outcomes: members-only digital health newsletters research reports. @ExitsOutcomes Before: Founder, MobiHealthNews (acq'd) Tip? DM for Signal.
Joined October 2008
- Tweets 5,083
- Following 4,266
- Followers 25,845
- Likes 2,079
122 Photos and videos
Pinned Tweet
16 May 2020
👀 from an early subscriber (VC) to @ExitsOutcomes —> exitsandoutcomes.com/pricing…
8
1
39
Brian Dolan retweeted
10 Dec 2024
can't recommend @bddol 's exit & outcomes publication enough - the databases alone are interesting
exitsandoutcomes.com/pricing…
1
8
1,584
Brian Dolan retweeted
21 Sep 2023
Now you’re just straight up stealing all my best client advice. Including that they need to subscribe to @ExitsOutcomes
1
3
604
Brian Dolan retweeted
20 Sep 2023
Love @ExitsOutcomes. Among the best healthcare analysts around.
20 Sep 2023
The SWORD Health Report is yet another banger by @ExitsOutcomes
My fav insight: don't try and sell to the big boyz from day 1
Almost never works. Instead target small customers, get their feedback, and use them for your marketing
1
1
6
1,691
Brian Dolan retweeted
25 Aug 2023
Won't spill all the beans, but you can find the complete report here: exitsandoutcomes.com/the-spr…
(don't forget to subscribe to @bddol's blog)
1
1
1,025
Brian Dolan retweeted
25 Aug 2023
The Spring Health Report is another banger by @ExitsOutcomes (@bddol). My top three favorite insights:
(1) Sell then build
Doesn't matter if this is your 1st product or a feature you'll spend significant time on. Make sure people want to pay (extra)
1
3
17
6,948
22 May 2023
Quite the turn of events: I speculated last week that the mystery buyer of Pear Therapeutics' core assets was its ex-CEO. The purchase agreement reveals this to be true. McCann, under the name Harvest Bio, seems intent on resurrecting Pear using the following assets --> (1/3)
3
15
47
12,000
22 May 2023
The judge presiding over the bankruptcy court proceedings still needs to sign off on the asset sales --so this isn't a done deal yet. And some have already objected to the sale to McCann -- including the federal government and the South Carolina Department of Corrections. (3/3)
1
1
4
1,533
22 May 2023
Who is funding McCann's bid to resurrect Pear? A Boston-based, stealthy investor named T.Rx Capital. The fund T.Rx is using to back up McCann's bid was set up Jan 2023. Former Pear exec Michael Langer appears to be a co-founder and managing director of T.Rx too.
3
6
1,215
19 May 2023
In this week's @ExitsOutcomes Friday newsletter:
- Was ex-CEO the mystery buyer in Pear's asset auction?
- Woebot pauses its postpartum depression prescription digital therapeutic
-Swing Therapeutics gets FDA De Novo but PDT go-to-market is its own virtual clinic, Swing Care
1
7
1,059
Brian Dolan retweeted
16 May 2023
This report from @bddol on @wearebighealth is a must read for everyone interested in the Dtx space
The most interesting part to me was that Big Health uses its clinical research programs as a moat - see a slide of their sales deck (2021):
3
3
22
6,153
Brian Dolan retweeted
10 Apr 2023
excellent thread - and I think your point around digital therapeutics building out full clinics is already happening (see below h/t @bddol)
IMO the path forward is to build out opinionated care models that target a specific disease area, which I think dTX can be great for
1
2
18
2,447
Brian Dolan retweeted
10 Apr 2023
Pear Therapeutics announced that they are filing for bankruptcy, which made me sad. Although my thinking has changed over time on DTx, I am still a fanboy at heart, feel pretty lucky to have seen this whole arc and feel like reminiscing. forbes.com/sites/katiejennin…
18
24
125
51,081
23 Mar 2023
Which health tech-focused (entirely or partially) investors/VCs have worthwhile newsletters, podcasts, or blogs that are more under-the-radar than others?
4
1
1
1,444
17 Mar 2023
No surprise here: Pear Therapeutics is looking for a buyer. The company isn't going to hold a Q4/FY22 investor call anymore. Pear was the first prescription digital therapeutics company to go public via SPAC.
4
5
29
18,159
17 Mar 2023
A few weeks ago when Pear's chief commercial officer departed and its stock dropped below $1 for the first time, I wondered if we'd see a buyer step up soon (Exits & Outcomes Issue 184):
1
2
3
1,781
Brian Dolan retweeted
18 Feb 2023
i think this approach makes a lot more sense from a payment and value capture perspective. and for controlling the experience and making sure the DTx tools are used uniformly and effectively.
1 Dec 2022
I still believe that, over a long enough time horizon, all DTx companies become virtual care companies.
2
2
9
2,022
Brian Dolan retweeted
18 Feb 2023
pretty interesting via @bddol - a digital therapeutics company spinning out a virtual clinic
I suspect as more digital therapeutics struggle to get payer clinician adoption, this becomes a more popular go-to-market especially to get evidence
2
3
23
8,731
22 Dec 2022
Breaking news in AliveCor-Apple suits: ITC decided to ban importation of Apple Watch bc it infringes AliveCor patents. But: Because Apple just won a case in the USPTO/PTAB court... this ITC decision won't be enforced until the PTAB case goes through appeals process (1/2)
1
2
10
10,840
22 Dec 2022
Apple healthcare provider partners half a dozen supporters in Congress tried to convince the ITC that the public interest was better served by not banning import of Apple Watches bc they were used in so many health studies and programs. The ITC wasn't swayed by that.
1
2
994
22 Dec 2022
Here's the language re: the suspension of this order pending the outcomes of the appeals process in the PTAB case that Apple just won against AliveCor re: the same patents:
809